|Articles|August 1, 2013

How RBM Impacts the Way Sanofi Handles Monitoring

Lori Convy, assistant director clinical research monitoring, Sanofi discusses risk-based monitoring

Lori Convy, assistant director clinical research monitoring, Sanofi discusses risk-based monitoring.

Newsletter

Stay current in clinical research with Applied Clinical Trials, providing expert insights, regulatory updates, and practical strategies for successful clinical trial design and execution.

Related Content

© ABCDstock - © ABCDstock - stock.adobe.com

Beyond Patient Centricity: What Rare Disease Research Gets Right

BySylvain Berthelot

September 4th 2026

The Unquantified Value of RBQM: Reduced Rework, Data Integrity, and Inspection Readiness

ByAbigail Dirks, MS,Sylviane de Viron,Andy Studna, Senior Editor

September 4th 2026

ACT Brief: Time Savings as RBQM Value Driver, FDA Tightens Foreign Trial Oversight, and Trusted Research Environments Versus Flat Files

ByAndy Studna, Senior Editor

September 4th 2026

© mod - © mod - stock.adobe.com

FDA Reaffirms GCP Standards Amid Growing Concerns Over Foreign Clinical Trial Data

ByAndy Studna, Senior Editor

September 3rd 2026

Why Time Savings Is the Largest Driver of RBQM's Financial Value

ByAbigail Dirks, MS,Sylviane de Viron,Andy Studna, Senior Editor

September 3rd 2026

Trending on Applied Clinical Trials Online

Fortrea to Acquire Worldwide Clinical Trials' Early Phase Services Division in $45 Million Deal

From Perspective to Action: Addressing the Real Cost Pressures in Clinical Trial Budgeting

Agentic AI and the Administrative Backbone of Clinical Trials: Why the Operating Model Has to Change First

Why Time Savings Is the Largest Driver of RBQM's Financial Value

FDA Reaffirms GCP Standards Amid Growing Concerns Over Foreign Clinical Trial Data